more

Amgen (AMGN)

(Delayed Data from NSDQ)

$312.47 USD

-2.25 (-0.71%)

Updated May 17, 2024 04:00 PM ET

After-Market: $312.53 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Bristol-Myers Announces Sale of Celgene's Otezla to Amgen

by Zacks Equity Research Published on August 27,2019

Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

by Zacks Equity Research Published on August 27,2019

Style Box ETF report for FLQL

Top Ranked Momentum Stocks to Buy for August 26th

by Zacks Equity Research Published on August 26,2019

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 26th.

finance
gold

Amgen Presents Positive Data From Rituxan Biosimilar Study

by Zacks Equity Research Published on August 23,2019

Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.

biotechs

Amgen (AMGN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on August 22,2019

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMGNNegative Net Change

Here's Why Allergan is Outperforming Its Industry Of Late

by Zacks Equity Research Published on August 20,2019

Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

pharmaceuticals

AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

by Zacks Equity Research Published on August 19,2019

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

pharmaceuticals

Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research Published on August 14,2019

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

by Zacks Equity Research Published on August 14,2019

Key highlights of the past week include collaborations, and other regulatory and pipeline news.

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

by Zacks Equity Research Published on August 14,2019

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

medical

Top Ranked Income Stocks to Buy for August 14th

by Zacks Equity Research Published on August 14,2019

Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 14th.

finance